Skip to main content
Profile picture for Jack Cush, MD

Jack Cush, MD

Dr. Cush is the Executive Editor of RheumNow.com and also Co-Edits the online textbook RheumaKnowledgy.com. 
  
Dr. Cush's interests include medical education, novel drug development, rheumatoid arthritis, spondyloarthritis, drug safety, and Still's disease/autoinflammatory syndromes. He has published over 140 articles and 2 books in rheumatology.
 
He can be followed on twitter: @RheumNow

Articles By Jack Cush, MD

arthritis.RA_.Xray_.hands_.jpg (keep)

Immune Checkpoint Inhibitor Safety with Pre-existing Rheumatoid Arthritis

Lancet Rheumatology has published a retrospective analysis showing patients receiving immune checkpoint inhibitors (ICI) for cancer have the same outcomes (mortality and severe immune-related adverse events (irAEs)) even when they have pre-existing rheumatoid arthritis (RA).

Read Article
RheumNow Podcast square

The Match Game (4.14.2023)

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com, including Rheumatology success in the NRMP MATCH, Cocaine vasculitis and worrisome safety risks with Biologics and tsDMARDs.

Read Article
Interview,woman

Why I Hire Women

Organizational psychologist Adam Grant points to a metanalysis of 63 studies, showing that women who assert their ideas, make direct requests, and advocate for themselves are liked less, AND they are also less likely to get hired. For me, these are exactly the attributes I am hiring - ideas, assertiveness, speaking up, advocating.

Read Article
pill,pain,med,hand

Pain and Opioid Updates

Today, the CDC and FDA provided new updates on the scope of pain in the USA and guidance on the use of opioids. MMWR April 14, 2023

Read Article
computer screen safety

RA Patients on Biologics and tsDMARDs are still High Risk

A new Swedish ARTIS registry study of key safety outcomes in rheumatoid arthritis (RA) patients receiving either targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs, including Janus Kinase inhibitors (JAKi)), has been updated and affirms previously held risks.

Read Article
RA,polyarticular,black,rheumatoid

Best Treatments for Immune Checkpoint Inhibitor-associated Arthritis

A retrospective study of cancer patients who developed immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA) shows that biologic DMARDs were more effective than conventional synthetic DMARDs (csDMARDs) in rapid control of arthritis.

Read Article
lungs,art,red

Clinical Profile of RA-associated Interstitial Lung Disease

A prospective, cross-sectional analysis of patients with rheumatoid arthritis (RA) shows those with interstitial lung disease (ILD) tend to be older, obese and have a smoking history.

Read Article
LiveVote.jpg

Rheumatologist - Work-Life Survey Results

During the week of April 3, 2023, registered Rheumatologists responded to an email survey regarding work-life balance. The following are the results from 190 respondents - 53% were male (47% female) and 94% were from the USA.

Read Article
RheumNow Podcast square

“You Can Have it All” (4.7.2023)

Dr. Jack Cush reviews the news and highlights from our "Women in Rheumatology" Campaign from last week on RheumNow.com

Read Article
epilepsy,brain,seizure,CVA

Antiphospholipid Antibodies With Incident Cardiovascular Events

Are antiphospholipid antibodies (aPL) associated with atherosclerotic cardiovascular (ASCVD) event risk?  A cohort study has shown that aPL Abs are found in a substantial proportion of adults with ASCVD events and finding both positive aCL IgA and aβ2GPI IgA Abs independently predicted futur

Read Article
×